Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity

被引:42
作者
Fischel, JL
Formento, P
Ciccolini, J
Rostagno, P
Etienne, MC
Catalin, J
Milano, G
机构
[1] Ctr Antoine Lacassagne, Oncopharmacol Unit, F-06189 Nice 2, France
[2] Sch Pharm, Pharmacokinet Unit, Marseille, France
关键词
5-fluorouracil; oxaliplatin; drug interactions; WiDr cell line;
D O I
10.1038/sj/bjc/6600185
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The combination of 5-fluorouracil-folinic acid and oxaliplatin has led to a significant improvement of chemotherapy efficacy in advanced pretreated colorectal cancer. The objective of the present study was, considering the oxaplatin-5-fluorouracil-folinic acid combination, to examine the impact of one given drug on the cellular determinants of cytotoxic activity of the other drug. These cellular factors were analysed on the human colon cancer cell dine WiDr in clinically relevant conditions of drug exposure ('De Gramont' schedule) with oxaliplatin-folinic acid during 2 h followed by 5-fluorouracil 48 h. The DNA binding of oxaliplatin was significantly reduced by the presence of 5-fluorouracil but this effect was time-dependent and after 50 h the platinum incorporated into DNA was identical in controls and in the drug combination. in the presence of oxaliplatin, there was less formation of FUH2 which is the first catabolite produced in the cascade of 5-fiuorouracil metabolic degradation. The effects of drugs on cell cycle were quite different from one drug to the other with oxaliplatin inducing a shift towards G(2) accumulation and 5-fluorouracil-folinic acid to a greater proportion of cells in G(1) - S. When oxaliplatin and 5-fluorouracil-folinic acid were combined the cell cycle effects were very similar to that of the 5-fluorouracil-folinic acid sequence alone. Oxaliplatin was able to reduce thymidy ate synthase activity with a marked impact 28 h after the beginning of cell exposure to the drug. The 5-fluorouracil-folinic acid drug sequence led to a profound reduction in thymidylate synthase activity and this decrease was not markedly enhanced by the presence of oxaliplatin. Regarding apoptosis, chances in mitochondrial membrane permeability were observed in the presence of the tested drugs and the impact of 5-fluorouracil-folinic acid was greater than that of oxaliplatin, The addition of oxaliplatin did not amplify the action of 5-fluorouracil-folinic acid upon mitochondrial membrane permeability change, The presence of oxaliplatin itself did not modify the intracelluar concentration of total reduced folates. The fact that oxaliplatin may reduce 3-fluorouracil catabolism could be central in explaining the supra-additive interaction between these drugs. (C) 2002 Cancer Research UK.
引用
收藏
页码:1162 / 1168
页数:7
相关论文
共 36 条
[1]   Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen [J].
André, T ;
Louvet, C ;
Raymond, E ;
Tournigand, C ;
de Gramont, A .
ANNALS OF ONCOLOGY, 1998, 9 (11) :1251-1253
[2]  
Backus HHJ, 2000, ONCOL RES, V12, P231
[3]   A ROLE FOR DIHYDROPYRIMIDINE DEHYDROGENASE AND THYMIDYLATE SYNTHASE IN TUMOR SENSITIVITY TO FLUOROURACIL [J].
BECK, A ;
ETIENNE, MC ;
CHERADAME, S ;
FISCHEL, JL ;
FORMENTO, P ;
RENEE, N ;
MILANO, G .
EUROPEAN JOURNAL OF CANCER, 1994, 30A (10) :1517-1522
[4]  
BUNNI M, 1988, CANCER RES, V48, P3398
[5]  
CARMICHAEL J, 1987, CANCER RES, V47, P936
[6]   QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS [J].
CHOU, TC ;
TALALAY, P .
ADVANCES IN ENZYME REGULATION, 1984, 22 :27-55
[7]  
CHU E, 1993, MOL PHARMACOL, V43, P527
[8]  
Ciccolini J, 2000, CLIN CANCER RES, V6, P1529
[9]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[10]  
Diasio RB, 2000, ONCOLOGY-NY, V14, P19